Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Description

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

Conditions

Atopic Dermatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Condition
Atopic Dermatitis
Intervention / Treatment

-

Contacts and Locations

Boston

Boston Children's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female participants ≥6 to 65 yrs of age
  • 2. Meet AD Standard Diagnostic Criteria
  • 1. Enrollment in another clinical trial
  • 2. Hypersensitivity to an agent used for the skin decolonization protocol
  • 3. Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
  • 4. Phototherapy for AD within 4 weeks
  • 5. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
  • 6. Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
  • 7. Bleach baths within 7 days of the first Visit
  • 8. Use of oral or topical antibiotics within 21 days of the beginning of the study
  • 9. Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
  • 10. History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
  • 11. Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
  • 12. Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
  • 13. Febrile illness at time of visits
  • 14. Suspected immune deficiency or family history of primary immunodeficiency

Ages Eligible for Study

6 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Boston Children's Hospital,

Wanda Phipatanakul, MD. MS., PRINCIPAL_INVESTIGATOR, Boston Children's Hospital

Study Record Dates

2027-09-15